908 Devices raised its 2026 outlook due to accelerating demand for handheld detection devices. Raised 2026 outlook combined with surging handheld detection demand indicates major positive shift in core product trajectory.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | 1 | — | — | — | 2 | 1 | 3 | 8 | 8 | 2 | 7 | 2 |
| total | individual payouts | |
|---|---|---|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 145.68 | 68.92 | 112.97 | 101.53 |
| Receivables | 8.99 | 8.85 | 11.33 | 11.71 |
| Inventory | 14.94 | 10.89 | 12.99 | 14.37 |
| Other | — | — | — | — |
| 173.79 | 103.06 | 144.56 | 132.02 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 1.19 | 1.37 | 1.59 | 2.71 |
| ST’ Debt | — | — | — | — |
| Other | — | — | 16.03 | 29.52 |
| 22.55 | 25.15 | 34.06 | 49.42 |
| 10y | 5y | 3y | |
| Sales | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 13.38 | 16.07 | — | — |
—
|
| ’25 | 11.78 | 13.04 | 14.01 | 17.38 |
56.20
|
| ’24 | 7.42 | 11.46 | 14.52 | 14.34 |
47.75
|
| ’23 | 9.49 | 12.09 | 14.30 | 14.35 |
50.23
|
| ’22 | 8.31 | 11.11 | 15.80 | 11.64 |
46.85
|
| ’21 | 5.54 | 8.28 | 12.55 | 15.84 |
42.21
|
| ’20 | 4.00 | 11.13 | 6.05 | 5.72 |
26.89
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 1.21 | 3.17 | — | — |
—
|
| ’25 | (15.02) | (5.78) | (4.20) | 1.32 |
(23.69)
|
| ’24 | (9.36) | (13.04) | (5.61) | (2.24) |
(30.25)
|
| ’23 | (10.65) | (7.88) | (4.60) | (1.93) |
(25.06)
|
| ’22 | (0.47) | (10.41) | (4.94) | (5.12) |
(20.93)
|
| ’21 | (9.63) | (7.30) | (2.92) | (9.22) |
(29.08)
|
| ’20 | (3.17) | (3.23) | 8.20 | 2.33 |
4.13
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 1.17 | 3.01 | — | — |
—
|
| ’25 | (15.18) | (5.91) | (4.88) | 1.33 |
(24.64)
|
| ’24 | (10.26) | (12.39) | (5.76) | (2.43) |
(30.85)
|
| ’23 | (11.83) | (8.20) | (4.81) | (2.26) |
(27.10)
|
| ’22 | (1.08) | (10.48) | (5.68) | (5.73) |
(22.97)
|
| ’21 | (9.64) | (7.92) | (2.98) | (9.27) |
(29.82)
|
| ’20 | (3.26) | (3.32) | 8.37 | 2.33 |
4.12
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.32) | (0.32) | — | — |
—
|
| ’25 | 1.23 | (0.37) | (0.41) | 0.10 |
0.54
|
| ’24 | (0.33) | (0.37) | (0.84) | (0.56) |
(2.12)
|
| ’23 | (0.39) | (0.29) | (0.22) | (0.23) |
(1.13)
|
| ’22 | (0.30) | (0.26) | (0.20) | (0.31) |
(1.07)
|
| ’21 | (0.22) | (0.27) | (0.19) | (0.12) |
(0.79)
|
| ’20 | (0.11) | 0.08 | (0.07) | (1.48) |
(2.35)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 6.87 | 4.85 | 1.81 | 1.92 | — | — | — |
Low Price
|
| — | — | — | — | ‡‡‡‡ | ‡‡‡‡ | 26.63 | 12.51 | 11.16 | 9.34 | — | — | — |
High Price
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 227 | 230 | 246 | 172 | — | — | — |
Employees
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.21 | 0.22 | 0.19 | 0.33 | — | — | — |
Revenue/Emp
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 46.85 | 50.23 | 47.75 | 56.20 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 55.54% | 50.41% | 51.31% | 50.58% | — | — | — |
Gross Margin
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (33.56) | (36.61) | (53.14) | (33.34) | — | — | — |
EBT
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (71.64%) | (72.89%) | (111.30%) | (59.33%) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (33.56) | (36.40) | (72.21) | 19.49 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.61 | 2.08 | 45.35 | 3.83 | — | — | — |
Depreciation
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.49 | 1.56 | 1.40 | 1.57 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.07) | (1.13) | (2.12) | 0.54 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.66) | (0.78) | (0.89) | (0.66) | — | — | — |
Cash Flow/Sh
|
| — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.06) | (0.06) | (0.02) | (0.03) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.73) | (0.84) | (0.91) | (0.69) | — | — | — |
Free CF/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 6.05 | 5.13 | 3.36 | 4.00 | — | — | — |
Book Value/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 31.49 | 32.24 | 34.08 | 35.90 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 9.38 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
PE Ratio
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 4.93 | 6.37 | 1.57 | 3.35 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.21 | 1.93 | 0.65 | 1.31 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.26 | 3.59 | 0.26 | 1.46 | ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.58) | (6.66) | (0.40) | (3.32) | — | — | — |
EV/FCF
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (20.93) | (25.06) | (30.25) | (23.69) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.04) | (2.04) | (0.60) | (0.95) | ‡‡‡‡‡ | — | — |
Capex
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (22.97) | (27.10) | (30.85) | (24.64) | — | — | — |
FCF
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 196.40 | 151.24 | 77.91 | 110.50 | — | — | — |
Working Cap'
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 16.47 | — | — | — | — | — | — |
Total Debt
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (171.95) | (145.68) | (68.92) | (112.97) | — | — | — |
Net Debt
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 190.60 | 165.49 | 114.59 | 143.70 | — | — | — |
Sh' Equity
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (13.33%) | (16.34%) | (39.84%) | 11.15% | — | — | — |
ROA
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | (118.60%) | (134.91%) | (78.54%) | (80.18%) | — | — | — |
ROIC
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (16.57%) | (20.44%) | (51.56%) | 15.09% | — | — | — |
ROE
|
908 Devices Inc. (MASS), a leader in handheld mass spectrometry for biopharma and industrial uses, trades at deeply depressed levels in early 2026, implying significant undervaluation with analyst targets signaling 50%+ average upside (up to 85%). Despite a volatile post-IPO journey—from mid-20s pricing in 2021 to $80 highs amid biotech hype, now down over 95%—revenue has compounded at over 20% annually to $59.6 million in 2024, with steady efficiency metrics like $200K+ per employee even as headcount doubled.
Persistent losses deepened to -$72 million in 2024 amid R&D and expansion costs, eroding margins and book value, yet a solid balance sheet persists with net cash, minimal debt, and ample working capital providing runway. Valuation multiples scream bargain—PS at 1.26, PB at 0.65—decoupled from improving fundamentals.
Insider buys by the CEO at recent lows signal confidence, aligning with forecasts of a 2025 revenue dip followed by 19%+ growth, halving losses en route to breakeven by 2027-2028. Risks from competition and macro headwinds loom, but this setup hints at a potential re-rating for patient investors—full analysis dissects the inflection ahead.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.